Healthcare
GSK plc(GSK)
Live Price
Offline$50.67
-2.84% today
1Y Change
+32.37%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $76.99B
- Revenue Growth
- +1.8%
- EPS Growth
- +119.0%
- Dividend Yield
- 3.4%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
GSK plc (GSK) is a Healthcare stock with a market cap of $76.99B and listed on NYSE. The stock last traded around $50.67 and up 32.4% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +1.8%, EPS growth of +119.0%, a dividend yield of 3.4%. What stands out right now is revenue +1.8%, EPS +119.0%, free cash flow +63.1% with operating margin 22.3% and ROIC 15.5%. The dividend matters to the case here, with a current yield around 3.4%. Valuation is more restrained than many high-expectation growth names at P/E 13.3 and price/sales 2.3. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines GSK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+1.8% vs +7.6% peer median
Operating Margin
Above sector median
+22.3% vs +19.4% peer median
P/E
Below sector median
13.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +1.8% and EPS at +119.0%, with operating margin around 22.3%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.4%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +1.8% | -1.7% | -0.3% |
2026 Feb 4, 2026 | +6.3% | +3.4% | +2.2% | -3.4% |
2025 Oct 29, 2025 | +17.5% | +2.2% | +1.7% | +4.6% |
Benchmark Edge
GSK vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GSK
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GSK Max Drawdown
-19.91%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GSK and SPY.
Company Overview
GSK plc
New York Stock Exchange
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
- Leadership
- Luke Victor Miels
- IPO Date
- Mar 28, 1980
- Employees
- 68.6k
- Street Address
- 980 Great West Road
- Mailing
- Brentford, TW8 9GS
- Region
- Brentford, GB
- Reporting Currency
- USD
- Investor Line
- 44 20 8047 5000
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 13.3
- EV/EBITDA
- 6.4
- Price/Sales
- 2.3
- Price/Book
- 4.3
Growth
- Revenue
- +1.8%
- EPS
- +119.0%
- Free Cash Flow
- +63.1%
Profitability
- Gross Margin
- 72.7%
- Operating Margin
- 22.3%
- Net Margin
- 17.8%
- ROE
- 35.8%
- ROIC
- 15.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.79
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.